Skip to main content

Treatment of a patient with myasthenia gravis using antibodies against CD25

Buy Article:

$43.00 plus tax (Refund Policy)

Kakoulidou M, Pirskanen-Matell R, Lefvert AK. Treatment of a patient with myasthenia gravis using antibodies against CD25.

Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2007.00919.x.

© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard. Objectives – 

To measure clinical and immunological parameters in a patient with myasthenia gravis (MG) treated with antibodies against CD25 (basiliximab, Simulect®). Patient and methods – 

Injections of basiliximab were given repeatedly together with cyclosporin A and corticosteroids for 9 months to a patient with severe MG. Her muscle function score was monitored and the immunological parameters were followed using ELISA, flow cytometry and radioimmunoassay. Results – 

The patient improved moderately and corticosteroid treatment could be withdrawn. The percentage of activated CD4+ T cells decreased during treatment, while that of ‘naïve’ T cells increased. The serum levels of sCD28, sCD152, sCD80, sCD86 and IL-10 decreased. The treatment was stopped due to repeated infections. Conclusion – 

Treatment with basiliximab appears to be suitable only for severely ill patients who do not respond to conventional treatments. However, careful monitoring of side effects is necessary.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: basiliximab; case study; myasthenia gravis

Document Type: Research Article

Affiliations: 1: Immunological Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 2: Department of Neurology, Karolinska Institutet, Stockholm, Sweden

Publication date: 2008-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more